Results 231 to 240 of about 23,252 (297)

When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung. [PDF]

Clin Cancer Res
Sinha A, Seervai RNH, Vlastelica KM, Fisher Thomas M, Hornick NI.   +4 more
europepmc   +1 more source

Monovalent mannose‐glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions

British Journal of Pharmacology, Volume 183, Issue 9, Page 1993-2008, May 2026.
Abstract Background and Purpose Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and ...
María Elena Angarita‐Planchez, Camila Leiva‐Castro, Ana M. Múnera‐Rodríguez, Macarena Martínez‐Bailén, Ana T. Carmona, Soledad López‐Enríquez, Francisca Palomares   +6 more
wiley   +1 more source

Comprehensive management of advanced lymphoepithelioma-like hepatocellular carcinoma with immune-related colitis: a case report and literature review. [PDF]

Front Oncol
Zhang J, Zhang X, Chen T, Zhu C.
europepmc   +1 more source

Proceedings: The effect of immunosuppression on cancer. [PDF]

, 1972
Penn, I, Starzl, TE
core  

Targeting Inflammation and Immune Regulation in Chronic Inflammation Associated Cancers

Cancer Science, Volume 117, Issue 5, Page 1209-1222, May 2026.
Chronic inflammation sustains activation of key inflammatory pathways, including Nuclear factor kappa B (NF‐κB), Interleukin‐6‐signal transducer and activator of transcription 3 (IL6‐STAT3), Phosphoinositide 3‐kinase/Akt (PI3K/Akt), and Wingless/β‐catenin (Wnt/β‐catenin) signaling. This promotes immune dysregulation through the expansion and functional
Lawan Rabiu, Mengzhu Chinn, Feng Chen, Yerkezhan Yerkinkazhina, Yuan Tian, Wei‐Guo Zhu   +5 more
wiley   +1 more source

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Vedolizumab induced acute interstitial nephritis. [PDF]

Oxf Med Case Reports
Fernandes D, Mathew A, Ferraro A, Samuel S.   +3 more
europepmc   +1 more source

Microbiome‐Based Modeling of CAR‐T Therapy Response in Lymphoma: Insights From Shotgun Metagenomics Sequencing

European Journal of Haematology, Volume 116, Issue 5, Page 646-662, May 2026.
ABSTRACT The interplay between the commensal microbiota and the mammalian immune system may influence the outcomes of T cell‐driven cancer immunotherapies. However, clinical studies supporting microbiota‐based interventions in chimeric antigen receptor T‐cell (CAR‐T) therapy remain scarce.
Rafael Hernani, Eliseo Albert, Carlos Hernani‐Morales, Sheila Zúñiga, Ana Benzaquén, Laura González‐Castillo, Ester Colomer, Júlia Morell, José Francisco Català‐Senent, José Luis Piñana, Estela Giménez, Ariadna Pérez, Juan Carlos Hernández‐Boluda, Ignacio Arroyo, Marcos Rivada, Teresa Barber, Teresa Alemany, Enric Santacatalina, Pilar Rentero‐Garrido, María José Terol, Rafael Díaz, David Navarro, Carlos Solano   +22 more
wiley   +1 more source

Microscopic colitis in alopecia areata: A gut-skin connection beyond the follicle. [PDF]

JAAD Int
Hirpara M, Greene R, Chapman M, Albers CG, Mesinkovska N.   +4 more
europepmc   +1 more source

Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR‐HCC (Lombardy Real‐World HCC Group)

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aim Dual immune checkpoint blockade with tremelimumab plus durvalumab (STRIDE) is an established first‐line therapy for unresectable hepatocellular carcinoma (uHCC); however, real‐world evidence on its safety, toxicity kinetics and liver function dynamics remains limited.
Andrea Casadei‐Gardini, Lorenzo Canova, Federica Tosi, Silvia Camera, Elisa Bocchero, Pietro Pozzoni, Martina Torchio, Salvatore Corallo, Daniela Costantino, Annamaria Stagno, Giulia Grizzi, Rita Gengarle, Gianluca Tomasello, Nasim Ansarin, Mariangela Bruccoleri, Katia Bencardino, Mara Persano, Martina Pino, Alessia Riva, Sara Vavassori, Lorenzo Argiento, Chiara Mazzarelli, Massimo De Giorgio, Elena Rota Caremoli, Margherita Rimini, Tiziana Pressiani, Lorenza Rimassa, Massimo Iavarone   +27 more
wiley   +1 more source